Evidence map›Paper›PMID 39877106›Full record

ArticlePostepy dermatologii i alergologii2024

Collision tumours: our recent experience.

Adam Zalewski, Iwona Chlebicka, Jacek C Szepietowski

Abstract read
In one paragraph

Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Adam ZalewskiDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Iwona ChlebickaDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Jacek C SzepietowskiDepartment of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Collision skin lesions (CSL) are rare clinical and pathological entities, posing significant diagnostic and therapeutic challenges. These lesions comprise at least two distinct cell populations - benign and/or malignant neoplasms - that are adjacent yet clearly demarcated. CSL were categorized as collision tumours into three types: two benign lesions, one benign and one malignant lesion, and two malignant lesions, with the most common being basal cell carcinoma (BCC) and melanocytic naevus. Aim: To analyse and present cases of collision skin lesions treated surgically in our Dermatosurgical Unit. Material and methods: A retrospective review was conducted on patients treated in our unit in 2021-2022, excluding lesions arising from preexisting conditions or located at the same anatomical site but separable upon examination. Results: Out of 838 patients, 4 cases of collision tumours were identified: one with two benign lesions and three with one benign and one malignant lesion, all histologically confirmed. Conclusions: Collision tumours, due to their rare occurrence and complex nature, represent a diagnostic challenge. Awareness and early detection, aided by dermoscopy, are crucial for effective management. Treatment should prioritize the more aggressive component of the tumour, with excisional biopsy being a favourable approach. Further research is needed to better understand the pathogenesis and optimize diagnostic and therapeutic strategies.

Indexed as

collision skin leasioncollision tumor

Identifiers

PMID39877106
PMCPMC11770567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.